STOCK TITAN

Aura Biosciences (AURA) Stock News, Aug-Nov 2022

AURA NASDAQ

Aura Biosciences, Inc. develops precision therapies for solid tumors designed to preserve organ function. The clinical-stage biotechnology company’s recurring updates center on bel-sar (AU-011), its lead candidate in late-stage development for early choroidal melanoma and in early-stage development for other ocular oncology indications and bladder cancer.

Company news also covers financial results, clinical-program business highlights, investor conference participation, executive leadership changes, and capital actions involving common stock and pre-funded warrants. Aura’s disclosures frequently connect pipeline progress with oncology indications, trial activity, liquidity planning, and governance developments.

Rhea-AI Summary

Aura Biosciences reported its Q3 2022 financial results, highlighting significant clinical advancements in its oncology programs. The company announced the global Phase 3 trial design for belzupacap sarotalocan in treating early-stage choroidal melanoma, marking a milestone in vision-preserving therapy. A first patient has been dosed in a Phase 1 study for non-muscle invasive bladder cancer. Financially, Aura’s cash position is $111.5 million, expected to fund operations until 2024. However, R&D and G&A expenses have increased, leading to a net loss of $15.9 million for Q3 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.88%
Tags
-
Rhea-AI Summary

Aura Biosciences Inc. (NASDAQ: AURA) has announced the initiation of startup activities for a global Phase 3 trial for its drug belzupacap sarotalocan (bel-sar), aimed at treating early-stage choroidal melanoma. This follows positive interim data from a Phase 2 trial presented at the American Academy of Ophthalmology. The trial will evaluate bel-sar's safety and efficacy compared to a sham treatment. Approximately 75 patients will be enrolled, with a focus on those with documented tumor growth to enhance trial efficiency.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.88%
Tags
-
Rhea-AI Summary

Aura Biosciences (NASDAQ: AURA), a clinical-stage biotechnology company, announced participation in key investor conferences. The executive team will present at the Stifel 2022 Healthcare Conference on November 16, 2022, at 10:55 a.m. ET, and hold a fireside chat at the 5th Annual 2022 Evercore ISI HealthCONx on November 29, 2022, at 8:25 a.m. ET. Webcasts of both events will be accessible on the company’s website for 90 days post-event. Aura specializes in virus-like drug conjugates for various oncology treatments, including ocular cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
conferences
Rhea-AI Summary

Aura Biosciences (NASDAQ: AURA) announced encouraging interim Phase 2 data for its first virus-like drug conjugate, belzupacap sarotalocan (AU-011), targeting early-stage choroidal melanoma. The data, presented at the American Academy of Ophthalmology 2022 Annual Meeting, showed a significant reduction in tumor growth rates (-0.296 mm/yr, p = 0.0007) and an 88.9% tumor control rate after three cycles of treatment. The therapy demonstrated favorable safety and a potential for vision preservation in patients lacking treatment options. A virtual Investor Day was scheduled to discuss these findings further.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.48%
Tags
-
Rhea-AI Summary

Aura Biosciences Inc. (NASDAQ: AURA) has announced the dosing of the first patient in a Phase 1 clinical trial of belzupacap sarotalocan, aimed at treating Non-Muscle Invasive Bladder Cancer (NMIBC). This trial marks a significant milestone in urologic oncology, addressing a high unmet medical need. The trial will enroll 23 patients to evaluate the safety and tolerability of the treatment. Previously, the FDA granted Fast Track designation for this candidate, facilitating more frequent consultations regarding its clinical development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.23%
Tags
-
Rhea-AI Summary

Aura Biosciences (NASDAQ: AURA) will present data from its Phase 2 trial for belzupacap sarotalocan (AU-011) at the American Academy of Ophthalmology (AAO) Annual Meeting, running from September 30 to October 3, 2022. The trial targets early-stage choroidal melanoma. A virtual Investor Day is scheduled for October 3, featuring discussions with ocular oncology experts about safety, efficacy results, and potential combinations with immune checkpoint inhibitors. The company aims to develop AU-011 for various oncology treatments, including ocular cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.12%
Tags
conferences clinical trial
Rhea-AI Summary

Aura Biosciences Inc. (NASDAQ: AURA) recently announced that Phase 2 data for its first virus-like drug conjugate (VDC), belzupacap sarotalocan (AU-011), will be presented at the ESMO 2022 Congress, taking place from September 9-13 in Paris. The presentation will focus on the safety of suprachoroidal administration for treating early-stage choroidal melanoma. The company aims to enhance treatment options for this severe form of eye cancer, currently in a dose escalation trial. Additional developments are planned for other oncology applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.45%
Tags
conferences clinical trial
-
Rhea-AI Summary

Aura Biosciences Inc. (NASDAQ: AURA) announced recent advancements in its leading candidate, belzupacap sarotalocan (AU-011), aimed at treating early-stage choroidal melanoma. Presentations at the EURETINA Congress will showcase interim safety results from a Phase 2 trial and final efficacy data from a Phase 1b/2 trial. The ongoing development focuses on both choroidal melanoma and its metastatic counterpart. Aura plans to submit an IND for choroidal metastases in the second half of 2022, emphasizing the drug's potential in ocular oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
conferences
-
Rhea-AI Summary

Aura Biosciences (NASDAQ: AURA) reported significant advancements in its clinical pipeline for belzupacap sarotalocan, aiming to treat non-muscle invasive bladder cancer (NMIBC) and early-stage choroidal melanoma. The company is set to dose the first patient in the Phase 1 trial for NMIBC in Q3 2022 and initiate a pivotal trial for choroidal melanoma in Q4 2022. Aura received FDA Fast Track designation for NMIBC, enhancing its development strategy. Financially, the company reported a net loss of $13.5 million for Q2 2022, with cash reserves expected to fund operations into 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.89%
Tags
Rhea-AI Summary

Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology firm, announced participation in a fireside chat at the 2022 Hybrid BTIG Biotechnology Conference on August 8, 2022, at 9:00 a.m. ET. The chat will feature CEO Elisabet de los Pinos and CFO Julie Feder. Aura is developing a novel class of virus-like drug conjugates (VDCs) for oncology, including its leading candidate, belzupacap sarotalocan (AU-011), aimed at treating ocular cancers. The company is also pursuing other applications in cancer therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.32%
Tags
conferences

FAQ

What is the current stock price of Aura Biosciences (AURA)?

Aura Biosciences (AURA) last closed at $6.98.

What is the market cap of Aura Biosciences (AURA)?

The market cap of Aura Biosciences (AURA) is approximately $726.4M.